xCELLigence RTCA Cardio

Monitors cardiomyocyte activity for cardiotoxicity assessment

Monitor cardiomyocyte activity for cardiotoxicity assessment

Real-time control and monitoring

Information

xCELLigence RTCA Cardio – Cardiomyocyte activity

The xCELLigence RTCA Cardio instrument monitors cardiomyocyte activity for cardiotoxicity assessment. The contraction-relaxation cycle of cardiomyocytes gives rise to a distinct, rhythmic fluctuation in impedance that is readily captured on the millisecond time scale. Changes in the intensity and periodicity in impedance are monitored in seconds or in days to assess cardiomyocyte contractility and viability in the presence of various drugs.

The xCELLigence RTCA Cardio instrument, which analyzes cells in an electronic 96-well microtiter plate format (E-Plate Cardio 96), is placed in a standard CO2 cell culture incubator and interfaces via a cable with analysis and control units that are housed outside the incubator. User friendly software allows for real-time control and monitoring of the instrument.

Key features:

Provides a high-throughput method for detecting functional cardiotoxicity effects on short- and long-term cardio beating activity and for general toxicity
Correlates findings with arrhythmogenic activity
Provides insight into compound mechanism of action

	Cardio	CardioECR
Recording in incubator	✓	✓
System
IMP electrodes	✓	✓
FP electrodes		✓
Electrical pacing function		✓
device
plate	96-well E-Plate	48-well E-Plate
Application
Cell attachment and viability	✓	✓
Contractility	✓	✓
FP (ion channels) assessment		✓
Acute assay (seconds to minutes)	✓	✓
Long-term assay (hours to days)	✓	✓


recording	Recording in incubator	96 wells, 12.9 ms	Up to 24 wells -1ms; all 48 wells – 2ms
	Field potential sampling rate	n/a	10 kHz
	Sampling capability	Simultaneous recording of impedance in 96 wells	Simultaneous recording of impedance and field potential electrodes in all 48 wells

stimulation	Stimulation voltage range	n/a	-2.5 V to +2.5 V
stimulation	Simultaneous stimulation	n/a	Up to 48 wells (across the entire plate)

Analyzer Application	Apoptosis	Cell Characterization	Cytotoxicity

	Proliferation	Stem Cells	Cardiotoxicity
Depth	34 cm
Height	16 cm
Operating Environment Relative Humidity	5-98 %
Operating Environment Temperature	15-40 °C
Sampling Format	96-well plate
Width	28 cm

Cardiac Disease Modeling The pathophysiological cellular phenotypes of genetically heritable heart diseases can be modeled using disease-specific human induced pluripotent stem cell cardiomyocyte (hiPSC-CM). Modeling enables broader understanding of the mechanisms leading to compromised electrical and contractile coupling.

Cardio Safety Toxicology Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) have been used to assess drug liability. The xCELLigence RTCA CardioECR system offers a unique multiplex detection method to probe and understand the underlying toxicity of compounds and pharmaceuticals.

Cardio Drug Discovery Human induced pluripotent stem cell cardiomyocytes (hiPSC-CM) offer an exciting new model system to test both the efficacy and toxicity of new therapeutic approaches, including inotropic compounds that serve to modulate the force of cardiomyocyte contractility.

The CiPA (Comprehensive In Vitro Proarrhythmia Assay) Initiative Driven by HESI, FDA and Safety Pharmacology Society, the CiPA initiative aims to evaluate potential modifications to current regulatory FDA guidelines for cardiac safety assessment. The xCELLigence RTCA CardioECR was selected as a core technology for validation and has participated in Phase I and II.

The xCELLigence RTCA Cardio system uses non-invasive, label-free biosensors to continuously evaluate cardiomyocyte health/function in real-time. Cardiomyocytes are seeded in a 96-well electronic microplate microtiter plate (E-Plate Cardio 96) designed with biosensor on bottom of each well. Application of a low voltage (less than 20 mV) establishes an electric current between the biosensors which is differentially modulated by the number of cells covering the biosensors, the morphology of those cells, and the strength of cell attachment (Figure 1A). Cardiomyocyte contraction/relaxation cycle can be dynamically monitored because it involves substantial changes in cell morphology and adhesion (Figure 1B). The fast data acquisition rate (12.9 ms for the entire 96-well plate) of the xCELLigence RTCA Cardio system provides high temporal resolution for viewing subtleties of the cardiomyocyte contraction/relaxation continuum. Flexible monitoring enables the study of both short- and long-term effect of compounds on cardiomyocyte health and function.

Software The user-friendly RTCA Cardio Software provides outstanding instrument control for flexible experiment setups, data acquisition, and data analysis. All instrument and experiment controls are contained in the software to simplify experiment setup and operation.

The RTCA Cardio instrument offers a way to monitor cardiotoxicity by measuring the fluctuation in impedance caused by cardiomyocyte activity. The contraction-relaxation cycle of cardiomyocytes gives rise to a distinct, rhythmic fluctuation in impedance that is readily captured on the millisecond time scale. Various assessments on drugs and pharmaceuticals can be studied in seconds to days by monitoring the changes in intensity and periodicity of the impedance. The xCELLigence RTCA Cardio instrument offers a 96-well microtiter plate format. The instrument is placed in a standard CO2 cell culture incubator and interfaces via a cable with analysis and control units that are housed outside the incubator. Key Features • Provides a high-throughput method for detecting functional cardiotoxicity effects on short- and long-term cardio beating activity and for general toxicity • Correlates findings with arrhythmogenic activity • Provides insight into compound mechanism of action Typical Applications • Cardiac disease modelling: Studying the phenotypes of genetically heritable heart diseases with disease-specific human induced pluripotent stem cell cardiomyocytes (hiPSC-CM). • Cardio Safety Toxicology: Assess the drugs liability and underlying toxicity of medicine and pharmaceuticals. • Cardio Drug Discovery: Test the efficacy and toxicity of pharmaceuticals with the usage of human induced pluripotent stem cell cardiomyocytes (hiPSC-CM).

Related instruments

xCELLigence RTCA CardioECR

Combines high frequency measurement of cell-induced electrical impedance with multi-electrode array technology to simultaneously assess cardiomyocyte contractility, viability, and electrophysiology

Combines high frequency measurement of cell-induced electrical impedance with multi-electrode array technology

Unprecedented level of detail

BioTek BioSpa 8

Automated Incubator

Information

xCELLigence RTCA Cardio – Cardiomyocyte activity

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Related instruments

Recently viewed instruments

Newsletter

BioSPX

Our Businesses

The Netherlands

Belgium